Efecto de la pentoxifilina sobre la proteinuria de rango nefrótico en glomerulopatías y nefropatía crónica del injerto. Resultados a los 6 meses de tratamiento
Resumen
La proteinuria ha sido considerada como expresión de daño o disfunción de la permeabilidad glomerular. Citoquinas proinflamatorias juegan un papel importante en el desarrollo de ese daño. Pentoxifilina (PTX )es un inhibidor de fosfodiesterasa y tiene efecto antiinflamatorio e inmunomodulador. Este estudio evaluó la eficacia de PTX para reducir la proteinuria de rango nefrótico en un grupo de pacientes con glomerulopatías primarias, diabética y nefropatía crónica del injerto (NCr.I). Diecisiete pacientes adultos con proteinuria > a 3.5 gr /24 hs con un filtrado glomerular calculado por MDRD > a 25 ml Imin fueron tratados con 400 mg de PTX 2 veces por día durante 6 meses sin suspender el tratamiento previo. Se compararon resultados antes y 6 meses después del tratamiento. Hubo una reducción de la proteinuria significativa (p=0.0006) y un aumento de la albúmina sérica también significativo (p=0.0002). No hubo cambios de la función renal y mejoraron el colesterol y los triglicéridos. Conclusión: PTX en dosis de 800 mg Idía es seguro y eficaz para reducir la proteinuria en afecciones glomerulares y en NCrI al margen del grado de función renal.
Citas
Keane W. Proteinuria: its c1inical importance and role in progressive renal disease. Am J Kidney Dis 2000; 35: S 97-105.
Igeki K, Ikemiya Y, Iseki K. Takishita, Proteinuria and the risk of developing end stage renal disease, Kidney Int 2003; 63: 1468-1474.
Remuzzi G, Schieppati A, Ruggementi P. Nephropathy in patients with type II diabetes N E J Med 2002; 346: 1145-1151.
Levey A S. Nondiabetic kidney disease. N E J Med 2002; 347:1505-1511.
Ruggementi P, Perna A, Remuzzi G. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int, 2003;63: 2254-2261.
Comprehensive Clinical Nephrology- 3rd. Edition 2007. John Feehally et al. Mosby Elsevier, p 187.
Antignac e. Molecular basis of steroid-resistant nephrotic syndrorne. Nefrología 2005, 25 (suppl. 2) 25-28.
Honkanen E, Treppo A M, Meri S, el al. Urinary excretion of cytokines and complement ScSb-9 in idiopathic membranous glomerulonephritis. Nephrol Dial Transplant 1994; 9: 1553-1559.
Honkanen E, Von Willebrand E, Treppo A M et al. Adhesion molecules and urinary tumor necrosis factor-alpha in idiopathic membranous glomerulonephritis. Kidney Int.l998; 53: 909-917.
RovinB H, Dol N, Tan Le. Monocytechemoattractan protein-I levels in patients with glomerular disease. Am J Kidney Dis 1996;27: 640-646.
Tam F W, Sanders J S, George A et al. Urinary monocyte chemoattractant protein-I is a marker of active renal vasculitis. Nephrol Dial Transplant 2004; 19: 2761-2768.
Zandi-Nejad K. Eddy A A, Glassock R J, Bremer B M. Why is proteinuria an ominous biomarker of progressive kidney disease? Kidney Int 2004; 66 (suppl 92) 576-589.
Jacoby D, Mohler III E R. Drug treatment of intermittent claudication, Drugs 2004; 64: 1657-1670.
Lin S L, Chen Y M, Chiang W C et al. Pentoxifylline a potential therapy for chronic kidney disease, Nephrology 2004; 9: 198-204.
Ducloux D, Bresson-Vauntrin C. Chalopin J. Use of pentoxifillyne in membranous nephopathy, Lancet 2001; 357: 1672-1673.
Galindo-Rodriguez G, Bustamante R, Esquivel Nava G et al. Pentoxifillyne in the treatment of refractory nephrotic syndrome secondary to lupus nephritis. J Rheumatol 2003; 30: 2382-2384.
Navarro J F, Mora C, Rivero A et al, Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects ofpentoxifillyne administration. Am J Kidney Dis 1999; 33: 458-463.
Navarro J F, Mora C, Muros M et al. Effects of pentoxifillyne administration on urinary N-acetylglucosaminidase excretion on type 2 diabetic patients; a short -terrn, prospective randomized study. Am J Kidney Dis 2003; 42: 2916-2929.
Shu K H, Wu M J, Cheng H et al. Effect of pentoxifillyne on graft function of renal transplant recipients complicated with chronic allograft nephropathy. Clin Nephrol 2007; 67 (S) 157-163.
Chen Y M, Lin S L, Chiang W C et aL Pentoxifillyne ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-I in patients with proteinuric primary glomerular diseases. Kidney Int 2006; 69: 1410-1415.
Levey A S, Greene T. Kusek J W, MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine (abstraer) J Am Soc Nephrol 2000 Sep; 11: 155A.
Paap C M, Simpson K S, Horton M W et al, Multiple -dose pharmacokinetics of pentoxifillyne and its metabolites during renal insufficiency. Ann Pharmacother 1996; 30: 724-729.
Shimizu S, Nakashima H, Masutami K et aL Anti-monocyte chemoattractant protein-l gene therapy attenuates nephritis in MRLlIpr mice. Rheumathology (Oxford) 2004; 43: 1121-1128.
Wu H, Wang Y, Tay Y et al. DNA vaccination with naked DNA encoding MCP-l and RANTES protects against renal injury in adriamycin nephrothy. Kidney Int 2005; 67: 2178-2186.
Aminorroaya A, Janghorbani M, Rezvanian H, Aminian T, Gharavi M, Amini M. Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus. Nephron Clin Pract. 2005;99(3):c73-7.
Harrnankaya O, Seber S, Yilmaz M. Combination of pentoxifillyne with angiotensing converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients, Renal Fail 2003; 25: 465-470.
Navarro J F, Mora C, Muros M et al. Additive antiproteinuric effect of pentoxifillyne in patients with type 2 diabetic under angiotensing U receptor blockade: a short-terrn, randomized, controlled trial. J Am Soc Nephrol 2005, 16: 2119-2126.
Brenner B M, Zagrobelny J. Clinicalrenoprotection trials involving angiotensing U-receptor antagonist and angiotensin-convertingenzyme inhibitors. Kidney Int 2003; 63 (Suppl. 82)377-585.
Rodriguez-Morán M, González G, Bermúdez-Barba M V et al. Effects oí pentoxifillyne on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: a double -blind, placebo- controlled randomized trial. Clin Nephrol 2006; 66(1): 3-10.
Ravera R E M, Weiss U et Al. Emerging therapeutic strategies in diabetic nephropathy. J Nephrol 2007; 20 (S 12) 23-32.
